Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11318132 Diversion-resistant opioid formulations

Patent 11318132 was granted and assigned to Elysium Therapeutics, Inc. on May, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Currently, there are no issues on this topic.

Find more entities like US Patent 11318132 Diversion-resistant opioid formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.